Abstract
BACKGROUND: The A.G.E. Interrupter serum has been developed in an oil-in-water emulsion to contain 30% proxylane, Cassia alata extract, blueberry and pomegranate extract, rhamnose, and gentiana lutea root extract. The technology has several patent ingredients as well as synergistic patents with proxylane, rhamnose, and new ones submitted for the new ingredients. An ex vivo model using this final formulation has shown upregulation of laminin-5, collagen IV, tropoelastin, and collagen III. Collagen IV and laminin are present in the dermal-epidermal junction (DEJ) and are factors in the basement membrane function. Over time, the DEJ decreases in height and in surface area, leading to weakened skin integrity and structure. The serum was tested to illustrate visible life in the jawline, forehead, cheek, and neck as well as instrumental testing showing visible improvement in the nasolabial fold and forehead wrinkle. AIM: To present a real-world case series that demonstrates the use of the A.G.E. Interrupter serum as an adjunctive therapy to collagen-stimulating procedures in a wide variety of patient ages and skin types. METHODS: Eight internationally recognized, licensed dermatologists with extensive experience in cosmetic and facial rejuvenation procedures were selected to participate in an expert panel. During the expert panel, dermatologists were asked to share 2 cases using the A.G.E. Interrupter serum in patients undergoing collagen-stimulating procedures. RESULTS: Following the panel discussion, seven patient cases were selected to illustrate the use of the A.G.E. Interrupter serum in conjunction with collagen-stimulating procedures to optimize patient outcomes and satisfaction. Experts found that daily A.G.E. Interrupter serum application post-procedure led to improved overall results and high patient satisfaction. CONCLUSION: This case series provides evidence for different integrated skincare regimens using the A.G.E. Interrupter serum in a variety of patients.